Bromocyclopropane (CAS 4333-56-6, molecular weight 120.98 g/mol) is a low-boiling liquid at ambient processing temperatures (68–70 °C at 760 mmHg, density 1.49 g/cm³ at 25 °C); direct incorporation into tablet matrices therefore follows a pre-adsorption route rather than classical wet granulation. The oral tablet application uses a liquid-on-carrier adsorbate prepared at a bromocyclopropane-to-carrier ratio of 1:4 to 1:6, with final tablet core drug loading held between 2.0% w/w and 8.0% w/w. Loadings above 10% w/w show a sharp increase in punch-tip sticking and peak compression force fluctuation because the porous carrier becomes saturated and releases free liquid during compression. The carrier is typically a mesoporous magnesium aluminometasilicate or porous dibasic calcium phosphate anhydride with oil adsorption capacity above 200 mL/100 g; the adsorptive blend is prepared in a low-shear planetary mixer fitted with a cooled jacket to hold the product temperature below 15 °C, limiting evaporative loss. Downstream production proceeds by blending the adsorbate with microcrystalline cellulose, crospovidone, colloidal silicon dioxide, and magnesium stearate in a V-blender for 15–25 min, followed by direct compression on a rotary tablet press using 8 mm round standard concave tooling at 8–14 kN compression force. Tablet hardness is maintained at 45–70 N, friability below 1.0% per USP <1216>, and disintegration time below 15 min in 900 mL water at 37 °C. Uniformity of dosage units is assessed per USP <905>; where bromocyclopropane is present below 25 mg per unit, content uniformity is required with acceptance value not more than 15.0. Dissolution follows USP <711> apparatus II at 50 rpm in pH 6.8 phosphate buffer. Compliance for the finished dosage form includes ICH Q3C residual solvent verification and FDA 21 CFR 211 current good manufacturing practice. The terminal product is a film-coated tablet in which a non-aqueous subcoat is applied to reduce moisture ingress into the drug-loaded core. Published data specific to bromocyclopropane tablet formulations are limited; the process parameters represent a development starting point derived from liquid API adsorption platforms rather than a registered monograph specification.

Why Does Low-Viscosity Fill Media Leakage Occur in HPMC Capsule Shells?

Liquid-filled hard capsules containing bromocyclopropane require a fill matrix with viscosity between 100 mPa·s and 800 mPa·s at 25 °C because lower viscosity allows capillary flow between the capsule body and cap. The formulation addition ratio is 5.0% w/w to 15.0% w/w bromocyclopropane in a medium-chain triglyceride or propylene glycol monocaprylate vehicle; the fill weight for size 0 HPMC capsules is controlled at 450–550 mg. The fill medium is degassed under vacuum before dosing to prevent bubble formation inside the positive-displacement pump. The downstream process uses a liquid capsule filling machine with in-line weight sorting; after filling, the cap and body are sealed with a 25–35% gelatin banding solution and dried at 35–40 °C for 4–6 h. Shell integrity is evaluated after 12 weeks at 40 °C/75% RH, with acceptance not exceeding 1.0% weight loss. Dissolution follows USP <711> apparatus II at 75 rpm in enzyme-free simulated gastric fluid; content uniformity is determined per USP <905>. Compliance includes ICH Q3C residual solvent assessment for the fill vehicle and FDA 21 CFR 211 manufacturing controls. The terminal product is a band-sealed liquid-filled hard capsule intended for oral administration.

When bromocyclopropane is formulated as a granule for unit-dose sachets, the production route shifts from direct compression to fluid-bed top-spray granulation because the drug substance is deposited onto a soluble carrier surface while residual ethanol is removed below the boiling point of the active. The formulation addition ratio is 1.0% w/w to 3.0% w/w bromocyclopropane in the finished dry granule; the carrier is a pre-blend of mannitol and pregelatinized starch. The drug is dissolved in 95% v/v ethanol and sprayed as a binder solution through a top-spray nozzle into a fluid-bed processor at inlet air temperature 45 °C, product temperature 28–32 °C, atomising air pressure 1.5 bar, and spray rate 8–12 g/min. The process is limited by evaporative loss: if product temperature exceeds 35 °C, the volatile fraction of bromocyclopropane escapes with the exhaust stream and the resulting granule potency falls below target before the drying endpoint is reached. After spraying, the granules are dried until residual ethanol is below 5000 ppm as permitted under ICH Q3C Class 3. Particle size distribution is controlled per USP <786> with not more than 10% retained on a 1000 µm sieve. Dissolution follows USP <711> apparatus II at 50 rpm in pH 6.8 buffer; uniformity is assessed per USP <905> for single-dose sachets. Compliance includes FDA 21 CFR 211 production controls. The terminal product is a single-dose granule sachet sealed in a polyethylene-aluminium-foil laminate.

Non-Aqueous Vehicle Composition for Oral Unit-Dose Solutions

The oral unit-dose solution application uses bromocyclopropane at 0.5% w/v to 2.0% w/v in a non-aqueous vehicle of propylene glycol and polyethylene glycol 400 because the compound has limited aqueous solubility. The vehicle is prepared in a stainless-steel mixing tank under nitrogen overlay to keep dissolved oxygen below 5% headspace concentration; bromocyclopropane is added at 15–20 °C and mixed with a low-shear propeller agitator for 30 min. The solution is passed through a 0.45 µm PVDF membrane filter and filled into amber glass vials with child-resistant closures to limit photodegradation and evaporative headspace loss. Compliance for the finished product includes USP <905> where the dose is metered in a single-unit container, ICH Q3C residual solvent verification for propylene glycol and PEG 400, and FDA 21 CFR 211 liquid oral manufacturing controls. The terminal product is an oral solution for unit-dose administration.

When Aseptic Filtration Replaces Terminal Sterilization for Hydrolytically Labile Injectables

When aseptic filtration replaces terminal sterilization for hydrolytically labile injectables, bromocyclopropane is formulated as a sterile injectable solution at 2 mg/mL to 10 mg/mL in a co-solvent vehicle of 30% v/v polyethylene glycol 400, 10% v/v ethanol, and water for injection adjusted to pH 5.0 with citrate buffer. The pH limit is a process boundary: alkyl bromide hydrolysis accelerates above pH 6.0 and at temperatures above 40 °C, so terminal moist-heat sterilization is replaced by double 0.22 µm PVDF sterile filtration under a Grade A laminar airflow environment compliant with ISO 14644-1:2015 Class 5 and EU GMP Annex 1. Filter membrane integrity is tested by pre-use and post-use bubble point per ASTM F838-20. Because the compound carries an alkyl bromide structural alert, an ICH M7 assessment is performed for the drug substance and injectable formulation; control limits are derived from the threshold of toxicological concern of 1.5 µg/day. The solution is filled into 5 mL Type I glass vials and stoppered with bromobutyl rubber closures. Osmolality is monitored with a freezing-point osmometer and adjusted to 280–320 mOsm/kg using sodium chloride or glycerol; subvisible particulate matter is controlled per USP <788> with acceptance not more than 6000 particles ≥ 10 µm and 600 particles ≥ 25 µm per container. Bacterial endotoxins must not exceed 0.5 EU/mg for an injectable product per USP <85>. The terminal product is a ready-to-use injectable solution in a single-dose vial.

Lyophilisation of a volatile liquid API becomes feasible only when bromocyclopropane is first complexed to reduce its vapour pressure during the drying phase. The formulation addition ratio is 5 mg/vial bromocyclopropane with hydroxypropyl-beta-cyclodextrin at a 1:5 molar ratio and mannitol 4.0% w/v as a crystalline bulking agent. The process uses aseptic filling into 10 mL Type I glass vials, pre-freezing to -40 °C at 0.5 °C/min, primary drying at -20 °C with chamber pressure 100 mTorr, and secondary drying at 20 °C for 6–10 h. Because the native boiling point of bromocyclopropane is 68–70 °C, uncontrolled sublimation during primary drying is the main batch-loss mode; the cyclodextrin complex suppresses the free fraction below the detectable headspace concentration at 100 mTorr. Product temperature is maintained below the collapse temperature determined by freeze-dry microscopy. Residual moisture is determined by Karl Fischer titration per USP <921> with acceptance below 1.0% w/w. Compliance includes USP <1> injections, USP <85> bacterial endotoxins, USP <790> visible particulates, and FDA 21 CFR 211 aseptic processing. The terminal product is a lyophilised cake for reconstitution with 5 mL water for injection before intravenous or intramuscular administration.